Clinical Trials
4
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
2 (50.0%)A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Cognitive ImpairmentAlzheimer Disease
- Interventions
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Theranexus
- Target Recruit Count
- 152
- Registration Number
- NCT03698695
- Locations
- 🇫🇷
CHU Bordeaux, Bordeaux, France
🇫🇷CHU Clermont Ferrand, Clermont-Ferrand, France
🇫🇷CHU Grenoble, Grenoble, France
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
Phase 2
Completed
- Conditions
- Parkinson Disease
- Interventions
- Drug: THN102 Dosage ADrug: THN102 Dosage BDrug: THN102 Dosage C
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- Theranexus
- Target Recruit Count
- 77
- Registration Number
- NCT03624920
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸MGH Neurological Clinical Research Institute, Boston, Massachusetts, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- Theranexus
- Target Recruit Count
- 20
- Registration Number
- NCT03182413
Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients
Phase 2
Completed
- Conditions
- Narcolepsy
- Interventions
- Drug: THN102 300/3Drug: THN102 300/27
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Theranexus
- Target Recruit Count
- 51
- Registration Number
- NCT02821715
- Locations
- 🇧🇪
RespiSom, Erpent, Belgium
🇫🇷CHU Pellegrin, Bordeaux, France
🇫🇷CHU Dijon Bourgogne, Dijon, France
News
Miglustat Shows Promise in Stabilizing Vision in Juvenile Batten Disease
Treatment with Batten-1 (miglustat) for 18 months showed no signs of deteriorating vision in patients with juvenile Batten disease.